Evidence map›Paper›PMID 30409796›Full record

Trial reportHaematologica2019

The sympathomimetic agonist mirabegron did not lower

Beatrice Drexler, Jakob R Passweg, Alexandar Tzankov, Martin Bigler, Alexandre Pa Theocharides, Nathan Cantoni, Peter Keller, Georg Stussi, Axel Ruefer, Rudolf Benz and 10 more

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02311569 (Effects of Sympathicomimetic Agonists on the Disease Course and Mutant Allele Burden in Patients With JAK2-mutated Myeloproliferative Neoplasms. A Multicenter Phase II Trial.), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02311569 phase2completednot on this map

Effects of Sympathicomimetic Agonists on the Disease Course and Mutant Allele Burden in Patients With JAK2-mutated Myeloproliferative Neoplasms. A Multicenter Phase II Trial.

TypeinterventionalSponsorSwiss Cancer InstituteRan2015 to 2016Enrolled39ConditionsMyeloproliferative Neoplasm, Primary Myelofibrosis, Essential Thrombocythemia, Polycythemia VeraArmsMirabegron
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Myelofibrosis.Blood · 2023
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. The Bone's Role in Myeloid Neoplasia.International journal of molecular sciences · 2020
    Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 11 institutions in 2 countries.

Beatrice DrexlerDivision of Hematology, University Hospital Basel and University of Basel, Switzerland.
Jakob R PasswegDivision of Hematology, University Hospital Basel and University of Basel, Switzerland jakob.passweg@usb.ch.
Alexandar TzankovInstitute of Pathology, University Hospital Basel and University of Basel, Switzerland.
Martin BiglerSwiss Group for Clinical Cancer Research, Bern, Switzerland.
Alexandre Pa TheocharidesHematology and Oncology, University Hospital Zurich and University of Zurich, Switzerland.
Nathan CantoniOncology, Hematology & Transfusion Medicine, Kantonsspital Aarau AG, Switzerland.
Peter KellerUniversity Clinic of Hematology and Central Hematology Laboratory, University Hospital Bern, Switzerland.
Georg StussiClinic of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Axel RueferDepartement Medizin, Luzerner Kantonsspital, Switzerland.
Rudolf BenzKantonsspital Muensterlingen, Switzerland.
Geneviève FavreCantonal Hospital Liestal, Switzerland.
Pontus LundbergDivision of Hematology, University Hospital Basel and University of Basel, Switzerland.
Ronny NienholdDepartment of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Switzerland.
Andrea FuhrerSwiss Group for Clinical Cancer Research, Bern, Switzerland.
Christine BiaggiSwiss Group for Clinical Cancer Research, Bern, Switzerland.
Markus G ManzHematology and Oncology, University Hospital Zurich and University of Zurich, Switzerland.
Mario BargetziOncology, Hematology & Transfusion Medicine, Kantonsspital Aarau AG, Switzerland.
Simon Mendez-FerrerWellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Department of Haematology, University of Cambridge, and National Health Service Blood and Transplant, Cambridge, UK.
Radek C SkodaDepartment of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Switzerland radek.skoda@unibas.ch.
Swiss Group for Clinical Cancer Research (SAKK)
University of Basel · CHSwiss Group For Clinical Cancer Research · CHKantonsspital Aarau · CHUniversity Hospital of Basel · CHInstitute of Oncology Research · CHKantonsspital Münsterlingen · CHLuzerner Kantonsspital · CHUniversity Hospital of Bern · CHUniversity Hospital of Zurich · CHUniversity of Zurich · CHWellcome/MRC Cambridge Stem Cell Institute · GB

Funding

Cancer Research UK 26670Medical Research Council MC_PC_12009
6 · The paper itself

Abstract

The β-3 sympathomimetic agonist BRL37344 restored nestin-positive cells within the stem cell niche, and thereby normalized blood counts and improved myelofibrosis in a mouse model of

Indexed as

Hematologic NeoplasmsJanus Kinase 2Mutation, MissenseMyeloproliferative DisordersNestinReticulinAcetanilidesAdultAmino Acid SubstitutionAnimalsFemaleFibrosisHumansMaleMiceMiddle AgedAcetanilidesJAK2 protein, humanJanus Kinase 2mirabegronNES protein, humanNestinReticulinSympathomimeticsThiazoles

Identifiers

PMID30409796
PMCPMC6442970
OpenAlexW2900152748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.